AR and hepatocellular carcinoma: We also compared niclosamide, compound #7, and compound #11 to both the AR antagonist enzalutamide and the kinase inhibitor standard-of-care HCC agent sorafenib at the clinically relevant concentration of 10 μM [47,48].